Abstract
In the early 20th century, researchers experimented with diverse compounds such as alum (aluminum salts), mineral oil, and killed mycobacteria to improve the immunogenicity of vaccines. These first empirical studies demonstrated the adjuvant activity of many substances, but several products also elicited significant local and systemic adverse reactions that precluded their use in human vaccine formulations. Alum adjuvant, first described in 1926, remains the only immunologic adjuvant used in human vaccines licensed in the United States.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vogel, F.R., Powell, M.F. (1995). A Compendium of Vaccine Adjuvants and Excipients. In: Powell, M.F., Newman, M.J. (eds) Vaccine Design. Pharmaceutical Biotechnology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1823-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1823-5_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5737-7
Online ISBN: 978-1-4615-1823-5
eBook Packages: Springer Book Archive